Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab with or without atezolizumab in advanced solid tumors
NL-OMON46722Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab and atezolizumab in hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), epithelial ovarian cancer (EOC) and 1 more (4 arms), sponsored by Sanofi. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 3 more. Started Aug 2018; status: completed.
02
Drugs
isatuximabatezolizumab
03
Conditions
hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)epithelial ovarian cancer (EOC)glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON46722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46722.